Fig. 3: Subgroup baseline analyses of overall survival. | British Journal of Cancer

Fig. 3: Subgroup baseline analyses of overall survival.

From: Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

Fig. 3: Subgroup baseline analyses of overall survival.The alternative text for this image may have been generated using AI.

5-FU 5-fluorouracil, BEV bevacizumab, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, FOLFIRI 5-FU, leucovorin, and irinotecan, FP fluoropyrimidine, FTD/TPI trifluridine/tipiracil, HR hazard ratio, IRI irinotecan, RAS rat sarcoma virus, y years.

Back to article page